Global Human Platelet Lysate Market Anticipated to Reach USD 344.0 Million by 2031

According to a recent market study published by Growth Market Reports, titled, “Global Human Platelet Lysate Market is segmented into by device type, by acuity level, by monitoring type, by patient group, by end-use and by region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 75.3 Million in 2022 and is expected to grow at a growth rate of 20.9% by the year 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6204

Human Platelet Lysate (hPL) is a cell culture growth supplement that is derived from human platelets. Human Platelet Lysate comprises abundant human growth factors, including PDGF, bFGF, EGF, TGF-beta1, VEGF, and other cytokines and proteins, which yield efficient results when culturing several types of human cells, particularly, human MSC (Mesenchymal Stem Cells) regardless of their tissue source.

Human platelet lysate (hPL) is considered as a valid substitute to fetal bovine serum (FBS) in the expansion of mesenchymal stromal cells (MSC), and it is commonly produced, starting from intermediate side products of whole blood donations. hPL is significantly enriched in chemokines, growth factors, adhesion, and immunologic molecules through freeze-thaw cycles. Regulatory agencies have approved cell treatment techniques that use hPL instead of FBS for cell multiplication, and its delivery to patients is regarded as safe.

Based on type, the global human platelet lysate market is segmented into heparin based human platelet lysate, fibrin-depleted human platelet lysate, xeno-free human platelet lysate, and others. The heparin-based human platelet lysate segment is expected to hold a significant share of the market during the forecast period, as it is increasingly applied in pathogen reduction technologies.

Based on product, the global human platelet lysate market is segmented into standard and customized. The standard segment is expected to hold a significant share of the market, due to the increasing demand for research activities in several research and academic institutes.

Based on form, the global human platelet lysate market is segmented into liquid and lyophilized. The liquid segment is expected to hold a significant share of the market, as it excludes the further processing of the product and saves manufacturing time.

Based on source, the global human platelet lysate market is segmented into platelet donation and platelet recovery. The platelet donation segment is expected to hold a significant share of the market, due to the increasing number of platelet donors globally.

Based on application, the global human platelet lysate market is segmented into research and therapeutic. The research segment is expected to hold a significant share of the market, due to ongoing research studies for novel therapies.

Based on end users, the global human platelet lysate market is segmented into pharmaceutical and biotechnology companies, academic & research institutes, stem cell research centers, contract research organizations, hospitals, and cell bank facilities. The pharmaceutical & biotechnology companies segment is anticipated to grow at a rapid pace in the near future, as personalized medicine provides suitable therapeutic options for the treatment of patients.

Based on distribution channel, the global human platelet lysate market is segmented into online and offline. The offline segment is expected to hold a significant share of the market during the forecast period owing to the benefits of quick product return without delay, availability of a variety of products, and personalized recommendations from staff.

The outbreak of COVID-19 has significantly impacted the Global human platelet lysate market. COVID-19 led to disruptions in healthcare systems globally, as resources were diverted to manage the surge in the number of COVID-19 cases. Elective procedures, including liver transplants, were postponed or canceled in many healthcare facilities to prioritize urgent and essential care. This resulted in a decline in the number of liver transplant procedures performed, leading to a decrease in the demand for liver donors. As of September 6, 2023, approximately 770,563,467 confirmed cases of COVID-19 were reported globally, of which about 6,957,216 died. COVID-19 cases have been registered in more than 223 countries and territories across the globe. Many individuals seeking medical care have postponed their hospital visits and medical treatment, due to concerns about potential exposure to the virus or restrictions on non-essential medical visits

As per Growth Market Reports by industry analyst Divyanka Sankhe, “Use of human platelet lysate devices to manage chronic diseases, such as diabetes and heart disease, has become increasingly important in the Global. The burden of chronic diseases is rising, due to lifestyle changes, such as sedentary lifestyles, poor diet, and smoking. Multi-parameter vital sign monitoring devices enable patients to monitor their condition at home, providing vital information to healthcare providers to help manage their disease and prevent complications.”

Supply chain management is an essential part of any business. Supply chain contains a series of steps to get products from their original state to the customers. These steps include transforming raw materials into final products, transporting those products, and distributing them to the end-users. End-users are the final step of the supply chain. End-users of human platelet lysate include pharmaceutical and biotechnology companies, academic & research institutes, stem cell research centers, contract research organizations, hospitals and cell bank facilities.

Market Key Developments

In July 2020, Sexton Biotechnologies launched the ‘T-Liven PR’ that associate closed system compatible packaging with discharge counter to a T-Cell growth release assay. T-Liven PR is validated Human Platelet Lysate (hPL) that has potential to produce highly potent CAR-T Cells.

In May 2022, AventaCell BioMedical Corp invited people in ISCT 2022 San Francisco to know about xeno-free human platelet lysate supplements that have potential to offer cell culture solutions.

In June 2021, Captivate Bio entered in an exclusive supply agreement with PL BioScience to expand its portfolio of human platelet lysate in North America.

The players in the Global Human Platelet Lysate Market include BioLife Solutions, Inc., Mill Creek Life Sciences, Inc., AventaCell BioMedical Corp, STEMCELL Technologies, Merck KGaA, Compass Biomedical, Inc., PL BioScience GmbH, Creative Biolabs, TCS Biosciences Ltd., PAN-Biotech and Life Science Group Ltd.

Report Scope:

Target Audience:

• Supply-side: Raw material suppliers, Manufacturer and distributors.

• Demand Side: Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, Stem Cell Research Centers, Contract Research Organizations, Hospitals, and Cell Bank Facilities.

• Regulatory Side: Approved regulatory bodies.

• Associations and Industry Bodies: U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).